KBLB Quote, Financials, Valuation and Earnings

Century Aluminum Co. has a net margin of -- compared to Kraig Biocraft Laboratories, Inc.'s net margin of 1.68%. Kraig Biocraft Laboratories, Inc.'s return on equity of -- beat Century Aluminum Co.'s return on equity of 10.05%.

Kraig Biocraft Laboratories, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Century Aluminum Co. has an analysts' consensus of $40.00 which suggests that it could fall by -12.45%. Given that Century Aluminum Co. has higher upside potential than Kraig Biocraft Laboratories, Inc., analysts believe Century Aluminum Co. is more attractive than Kraig Biocraft Laboratories, Inc..

Kraig Biocraft Laboratories, Inc. has a beta of 1.355, which suggesting that the stock is 35.464% more volatile than S&P 500. In comparison Century Aluminum Co. has a beta of 2.257, suggesting its more volatile than the S&P 500 by 125.673%.

Kraig Biocraft Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Century Aluminum Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kraig Biocraft Laboratories, Inc. pays -- of its earnings as a dividend. Century Aluminum Co. pays out -- of its earnings as a dividend.

Kraig Biocraft Laboratories, Inc. quarterly revenues are --, which are smaller than Century Aluminum Co. quarterly revenues of $632.2M. Kraig Biocraft Laboratories, Inc.'s net income of -$1.5M is lower than Century Aluminum Co.'s net income of $10.6M. Notably, Kraig Biocraft Laboratories, Inc.'s price-to-earnings ratio is 166.36x while Century Aluminum Co.'s PE ratio is 57.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kraig Biocraft Laboratories, Inc. is 179.21x versus 1.77x for Century Aluminum Co.. Usually stocks with elevated PS ratios are considered overvalued.

Kaiser Aluminum Corp. has a net margin of -- compared to Kraig Biocraft Laboratories, Inc.'s net margin of 4.68%. Kraig Biocraft Laboratories, Inc.'s return on equity of -- beat Kaiser Aluminum Corp.'s return on equity of 12.44%.

Kraig Biocraft Laboratories, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kaiser Aluminum Corp. has an analysts' consensus of $106.50 which suggests that it could fall by -13.46%. Given that Kaiser Aluminum Corp. has higher upside potential than Kraig Biocraft Laboratories, Inc., analysts believe Kaiser Aluminum Corp. is more attractive than Kraig Biocraft Laboratories, Inc..

Kraig Biocraft Laboratories, Inc. has a beta of 1.355, which suggesting that the stock is 35.464% more volatile than S&P 500. In comparison Kaiser Aluminum Corp. has a beta of 1.440, suggesting its more volatile than the S&P 500 by 43.951%.

Kraig Biocraft Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kaiser Aluminum Corp. offers a yield of 2.5% to investors and pays a quarterly dividend of $0.77 per share. Kraig Biocraft Laboratories, Inc. pays -- of its earnings as a dividend. Kaiser Aluminum Corp. pays out 107.4% of its earnings as a dividend.

Kraig Biocraft Laboratories, Inc. quarterly revenues are --, which are smaller than Kaiser Aluminum Corp. quarterly revenues of $843.5M. Kraig Biocraft Laboratories, Inc.'s net income of -$1.5M is lower than Kaiser Aluminum Corp.'s net income of $39.5M. Notably, Kraig Biocraft Laboratories, Inc.'s price-to-earnings ratio is 166.36x while Kaiser Aluminum Corp.'s PE ratio is 22.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kraig Biocraft Laboratories, Inc. is 179.21x versus 0.63x for Kaiser Aluminum Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Paramount Gold Nevada Corp. has a net margin of -- compared to Kraig Biocraft Laboratories, Inc.'s net margin of --. Kraig Biocraft Laboratories, Inc.'s return on equity of -- beat Paramount Gold Nevada Corp.'s return on equity of -34.36%.

Kraig Biocraft Laboratories, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Paramount Gold Nevada Corp. has an analysts' consensus of $1.70 which suggests that it could grow by 39.34%. Given that Paramount Gold Nevada Corp. has higher upside potential than Kraig Biocraft Laboratories, Inc., analysts believe Paramount Gold Nevada Corp. is more attractive than Kraig Biocraft Laboratories, Inc..

Kraig Biocraft Laboratories, Inc. has a beta of 1.355, which suggesting that the stock is 35.464% more volatile than S&P 500. In comparison Paramount Gold Nevada Corp. has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.562%.

Kraig Biocraft Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Paramount Gold Nevada Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kraig Biocraft Laboratories, Inc. pays -- of its earnings as a dividend. Paramount Gold Nevada Corp. pays out -- of its earnings as a dividend.

Kraig Biocraft Laboratories, Inc. quarterly revenues are --, which are smaller than Paramount Gold Nevada Corp. quarterly revenues of --. Kraig Biocraft Laboratories, Inc.'s net income of -$1.5M is higher than Paramount Gold Nevada Corp.'s net income of -$4.3M. Notably, Kraig Biocraft Laboratories, Inc.'s price-to-earnings ratio is 166.36x while Paramount Gold Nevada Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kraig Biocraft Laboratories, Inc. is 179.21x versus -- for Paramount Gold Nevada Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Solitario Resources Corp. has a net margin of -- compared to Kraig Biocraft Laboratories, Inc.'s net margin of --. Kraig Biocraft Laboratories, Inc.'s return on equity of -- beat Solitario Resources Corp.'s return on equity of -20.59%.

Kraig Biocraft Laboratories, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Solitario Resources Corp. has an analysts' consensus of $1.50 which suggests that it could grow by 110.03%. Given that Solitario Resources Corp. has higher upside potential than Kraig Biocraft Laboratories, Inc., analysts believe Solitario Resources Corp. is more attractive than Kraig Biocraft Laboratories, Inc..

Kraig Biocraft Laboratories, Inc. has a beta of 1.355, which suggesting that the stock is 35.464% more volatile than S&P 500. In comparison Solitario Resources Corp. has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.124%.

Kraig Biocraft Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solitario Resources Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kraig Biocraft Laboratories, Inc. pays -- of its earnings as a dividend. Solitario Resources Corp. pays out -- of its earnings as a dividend.

Kraig Biocraft Laboratories, Inc. quarterly revenues are --, which are smaller than Solitario Resources Corp. quarterly revenues of --. Kraig Biocraft Laboratories, Inc.'s net income of -$1.5M is higher than Solitario Resources Corp.'s net income of -$1.9M. Notably, Kraig Biocraft Laboratories, Inc.'s price-to-earnings ratio is 166.36x while Solitario Resources Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kraig Biocraft Laboratories, Inc. is 179.21x versus -- for Solitario Resources Corp.. Usually stocks with elevated PS ratios are considered overvalued.